Longevity Startup Doses First Human in Bid to Reverse AgeRelated Sight Loss
Jun 09, 2026
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss/
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service